title: Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens.
abstract: BACKGROUND
  Comprehensive literature on cervical cancer demonstrates, even today, the need for optimization of the timing of external-beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDR-BT) in the treatment of stage IIA/B-IIIB cervical carcinoma.
  
  
  METHODS
  210 patients with carcinoma of the cervix were treated in the Municipal Center of Oncoradiology between January 1991 and December 1996 (FIGO IIA: n = 10, FIGO IIB: n = 113, and FIGO IIIB: n = 87). Two regimens were compared: sequential radiation therapy (SRT) with 4 x 8 Gy HDR-BT to point A followed by EBRT, and continuous radiation therapy (CRT) in which 5 x 6 Gy HDR-BT to point A, one session per week, was integrated into the EBRT. A total dose of 68-70 Gy to point A and 52-54 Gy to point B was given in EBRT with SRT, five fractions per week were applied. Four fractions per week were applied in CRT, i. e., no EBRT was performed on the day of HDR-BT. Total doses to points A and B were identical in both regimens. Overall treatment time (OTT) amounted to 56 days for SRT and 35 days for CRT. Median follow-up time was 3.4 (2.5-4.2) years.
  
  
  RESULTS
  Progression-free 5-year-survival (PFS) was 71% in the CRT and 56% in the SRT group. Nevertheless, this difference was not statistically significant (p = 1.00), and the same was found in a subgroup analysis of the different tumor stages, showing, however, an unequivocal trend. Late bladder and rectal injuries occurred in 13% and 25%, respectively. Late rectal injuries were significantly more frequent with SRT than CRT (35 patients in the SRT and 18 patients in the CRT group; p = 0.037). This was due to the higher doses per fraction of HDR-BT in the SRT group. No difference was found regarding late bladder injuries (p = 0.837).
  
  
  CONCLUSIONS
  For the patients included in this study, no advantage has been found so far in using CRT, i. e., shortening the OTT by weekly integration of HDR-BT into EBRT. Nevertheless, an obvious trend exists. The dose of 8 Gy per fraction of HDR-BT in the SRT regimen was obviously too high. To achieve a significant improvement in local control and disease-free survival (DFS) as well as overall survival (OS), the combination with modern chemotherapy regimens and regional deep hyperthermia may rather be the treatment option.
authors.affiliation: Center of Oncoradiology, Uzsoki Hospital, Budapest, Hungary. mayera@hu.inter.net
authors.forename: Arpád
authors.initials: A
authors.lastname: Mayer
authors.forename: Csaba
authors.initials: C
authors.lastname: Nemeskéri
authors.forename: Csaba
authors.initials: C
authors.lastname: Petneházi
authors.forename: Gábor
authors.initials: G
authors.lastname: Borgulya
authors.forename: Szilvia
authors.initials: S
authors.lastname: Varga
authors.forename: Attila
authors.initials: A
authors.lastname: Naszály
mesh_terms: D001918:Brachytherapy / Q000379:methods; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D002584:Cervix Uteri / Q000473:pathology; D016001:Confidence Intervals; D003558:Cystoscopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017567:Karnofsky Performance Status; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D011860:Radiography, Abdominal; D011879:Radiotherapy Dosage; D012044:Regression Analysis; D016019:Survival Analysis; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*